 | Up a level |
Kim, Richard D; Sarker, Debashis; Meyer, Tim; Yau, Thomas; Macarulla, Teresa; Park, Joong-Won; Choo, Su Pin; Hollebecque, Antoine; Sung, Max W; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Trojan, Joerg; Zhu, Andrew X; Yoon, Jung-Hwan; Sharma, Sunil; Lin, Zhong-Zhe; Chan, Stephen L; Faivre, Sandrine; Feun, Lynn G; Yen, Chia-Jui; ... (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer discovery, 9(12), pp. 1696-1707. American Association for Cancer Research 10.1158/2159-8290.CD-19-0555
Bruix, Jordi; Tak, Won-Young; Gasbarrini, Antonio; Santoro, Armando; Colombo, Massimo; Lim, Ho-Yeong; Mazzaferro, Vincenzo; Wiest, Reiner; Reig, María; Wagner, Andrea; Bolondi, Luigi (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. European journal of cancer, 49(16), pp. 3412-3419. Elsevier 10.1016/j.ejca.2013.05.028
